Christine Ann Fox - 21 Jun 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role: Chief Financial Officer
Signature: /s/ Christine Fox
Issuer symbol: MREO
Transactions as of: 21 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2024, 18:13:45 UTC
Previous filing: 26 Jan 2024
Next filing: 27 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MREO	American Depositary Shares representing Ordinary Shares	Options Exercise	$0	+90,000	+900%	$0.000000	100,000	21 Jun 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MREO	Performance Based Restricted Stock Unit	Options Exercise	$0	+90,000		$0.000000	60,000	21 Jun 2024	American Depository Shares	90,000	$0.000000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2	Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).